


A Periodic Table of Biomarkers

Tumor-agnostic development strategies are gaining momentum as a way to treat solid and hematological tumors characterized by novel and existing biomarkers. Only 3 tumor-agnostic biomarker-targeted therapies are now approved globally and around 85 trials are currently evaluating 43 different biomarkers, of various types, with tissue-agnostic potential. Tumor-agnostic therapies face challenges simply by not fitting into established diagnostic, regulatory, and commercial paradigms. Given their potential to transform treatment algorithms and outcomes, however, development of tissue-agnostic biomarker-targeted therapies will continue to grow as the knowledge of oncology biomarkers increases.



CancerMPact®: Improving outcomes through empowered decision making. Start or continue your journey [here](#).

